Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Patient Education and Duloxetine for Multisystem FSD
NCT06232473Phase 4Recruiting
- Sponsor
- Aarhus University Hospital
- Start
- Jan 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of duloxetine in somatic symptom disorder (SSD) (6 arms), sponsored by Aarhus University Hospital. Primary endpoints: Short-Form Health Survey Aggregate Score and Clinical Global Improvement Scale. Started Jan 2024; status: recruiting.
02
Drugs
duloxetine
03
Conditions
somatic symptom disorder (SSD)
Beyond the preview
Go deeper on NCT06232473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232473.